Citius Pharmaceuticals Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while ProShares UltraPro Short QQQ ETF trades at $37.53. The key difference: Citius Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| CTXR | SQQQ | |
|---|---|---|
Market Cap | $20.01M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $92.95 |
52-Week Low | $0.48 | $36.31 |
Enterprise Value | $16.23M | — |
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.765, up 13.0% in the past 24 hours, with a bullish technical signal from moving averages. The company shows strong analyst support with 83% buy ratings but faces significant financial challenges including negative earnings, a -823.34% net income margin, and consecutive quarterly EPS misses. Recent news highlights expansion of LYMPHIR cancer treatment commercialization with 78% quarterly growth in new institutional accounts.
While technical indicators suggest near-term upside potential and analyst sentiment remains positive, fundamental weaknesses including substantial losses and negative cash flow from operations present significant investment risks. The company's ability to achieve profitability through its oncology drug commercialization will determine long-term shareholder value creation.
SQQQ, the ProShares UltraPro Short QQQ ETF, trades at $37.32, down 1.11% amid a bearish technical signal with moving averages indicating selling pressure. The ETF is designed to deliver -3x the daily performance of the Nasdaq-100, making it highly sensitive to tech sector volatility. Recent news highlights its role as a tactical hedge tool but warns of significant long-term erosion due to daily reset mechanics.
The outlook for SQQQ remains high-risk, suitable only for short-term hedging against Nasdaq declines. Key risks include volatility decay from daily leverage and dependency on precise market timing. Investor sentiment is cautious, with analysts emphasizing its unsuitability as a long-term holding despite potential tactical opportunities during tech selloffs.
Trailing returns across standard periods
Latest headlines on both assets
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →